Karamvir Yadav, Medical Oncologist in Jaipur, India, shared posts on X:
“AKT pathway is driving ~40% of ER+ breast cancer – but we’ve been oversimplifying it.
- Hotspots ≠ whole story.
- Rare variants still respond.
- PTEN biology is messy.
Capivasertib is changing the game.
Are you still treating only hotspot mutations?”
Title: Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer
Authors: Jacqueline J. Tao, Saumya D. Sisoudiya, Hanna Tukachinsky, Alexa B. Schrock, Ericka M. Ebot, Smruthy Sivakumar, Ethan S. Sokol, Neil Vasan
Read the Full Article.
The Throne Has Changed Hands: T-DXd Displaces T-DM1 in Post-Neoadjuvant HER2+ Breast Cancer
